Nyt fra tidsskrifterne
Søgeord (phase 3) valgt.
35 emner vises.
1
Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults who had Previously Received a Meningococcal ACWY Vaccine: Phase 3, Randomized, Controlled Clinical Study
Clinical Infectious Diseases
Tilføjet 26.12.2024
2
The Current and Future State of Vaccines for Lyme Disease
Clinical Infectious Diseases
Tilføjet 23.12.2024
3
SARS-CoV-2 resistance analyses from the Phase 3 PINETREE study of remdesivir treatment in nonhospitalized participants
Antimicrobial Agents And Chemotherapy
Tilføjet 20.12.2024
4
Weight and metabolic changes with long-acting cabotegravir and rilpivirine or bictegravir/emtricitabine/tenofovir alafenamide
Journal of Acquired Immune Deficiency Syndromes
Tilføjet 19.12.2024
5
Toward Evidence-based Recommendations for Laboratory Monitoring for Adolescents and Adults on Antiretroviral Therapy
Clinical Infectious Diseases
Tilføjet 11.12.2024
6
[Articles] Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial
Lancet Infectious Diseases
Tilføjet 6.12.2024
7
Lower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: Analysis from a Phase 3 randomized clinical trial (MELODY)
Clinical Infectious Diseases
Tilføjet 5.12.2024
8
Protocol for a multicentre randomised triple-blind controlled trial assessing the clinical efficacy of intra-articular platelet-rich plasma injections versus placebo in symptomatic knee osteoarthritis (PIKOA)
BMJ Open
Tilføjet 1.12.2024
9
[Articles] Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial
Lancet
Tilføjet 29.11.2024
10
Development of high titer anti-drug antibodies in a Phase 1b/2a infant clesrovimab trial are associated with RSV exposure beyond day 150
Journal of Infectious Diseases
Tilføjet 28.11.2024
11
Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial
American Journal of Respiratory and Critical Care Medicine
Tilføjet 28.11.2024
12
Non-inferiority study of purified Vero rabies vaccine – serum free in three-dose and two-dose pre-exposure prophylaxis regimens in comparison with licensed rabies vaccines
Clinical Infectious Diseases
Tilføjet 26.11.2024
13
[Articles] Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial
Lancet Infectious Diseases
Tilføjet 26.11.2024
14
Past, Present and Future of Phase 3 Vaccine Trial Design: Rethinking Statistics for the 21st Century
Clinical & Experimental Immunology
Tilføjet 23.11.2024
15
A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intraabdominal infections
Clinical Microbiology and Infection
Tilføjet 3.11.2024
16
[Articles] Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial
Lancet Infectious Diseases
Tilføjet 24.10.2024
17
[Articles] The effect of Plasmodium falciparum exposure and maternal anti-circumsporozoite protein antibodies on responses to RTS,S/AS01E vaccination in infants and children: an ancillary observational immunological study to a phase 3, randomised clinical trial
Lancet Infectious Diseases
Tilføjet 24.10.2024
18
[Perspectives] Fauci looks back
Lancet
Tilføjet 18.10.2024
19
Evaluating the validity and reliability of the Tswana adaptation of the MOS-HIV tool for health-related quality of life among HIV Sub-populations in Botswana: A study protocol
PLoS One Infectious Diseases
Tilføjet 12.10.2024
20
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study
BMJ Open
Tilføjet 10.10.2024
21
Combo COVID-19 and Flu mRNA Vaccine Falls Short of Total Flu Protection
Journal of the American Medical Association
Tilføjet 9.10.2024
22
[Articles] Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
Lancet Infectious Diseases
Tilføjet 8.10.2024
23
[Articles] Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months
Lancet Respiratory Medicine
Tilføjet 2.10.2024
24
A SONAR report on Nirmatrelvir/ritonavir-associated rebound COVID-19: Using new databases for evaluating new diseases
PLoS One Infectious Diseases
Tilføjet 26.09.2024
25
Interim safety and immunogenicity analysis of the EuCorVac‐19 COVID‐19 vaccine in a Phase 3 randomized, observer‐blind, immunobridging trial in the Philippines
Journal of Medical Virology
Tilføjet 25.09.2024
26
Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection
Journal of Infectious Diseases
Tilføjet 23.09.2024
27
Early warning and predicting of COVID-19 using zero-inflated negative binomial regression model and negative binomial regression model
BMC Infectious Diseases
Tilføjet 19.09.2024
28
Association Between SARS-CoV-2 Viral Load and COVID-19 Vaccination in 4 Phase 3 Trials
Journal of Infectious Diseases
Tilføjet 6.09.2024
29
[Articles] Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents
Lancet Infectious Diseases
Tilføjet 5.09.2024
30
Microbiome and Metabolome Restoration After Administration of Fecal Microbiota, Live-jslm (REBYOTA®) for Preventing Recurrent Clostridioides difficile Infection
Journal of Infectious Diseases
Tilføjet 24.08.2024
31
Efficacy and Safety of Pimodivir Combined with Standard-of-care in Hospitalized and Non-hospitalized High-risk Adolescents and Adults with Influenza A Infection
Journal of Infectious Diseases
Tilføjet 24.08.2024
32
[Articles] Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study
Lancet Infectious Diseases
Tilføjet 13.08.2024
33
[Articles] Efficacy and safety of Butantan-DV in participants aged 2–59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil
Lancet Infectious Diseases
Tilføjet 6.08.2024
34
Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial
Clinical Infectious Diseases
Tilføjet 5.08.2024
35
Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50–59 Years Compared to ≥60 Years of Age
Clinical Infectious Diseases
Tilføjet 5.08.2024